EP1506020A4 - Processes for inhibiting gene expression using polynucleotides - Google Patents

Processes for inhibiting gene expression using polynucleotides

Info

Publication number
EP1506020A4
EP1506020A4 EP03751760A EP03751760A EP1506020A4 EP 1506020 A4 EP1506020 A4 EP 1506020A4 EP 03751760 A EP03751760 A EP 03751760A EP 03751760 A EP03751760 A EP 03751760A EP 1506020 A4 EP1506020 A4 EP 1506020A4
Authority
EP
European Patent Office
Prior art keywords
polynucleotides
processes
gene expression
inhibiting gene
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03751760A
Other languages
German (de)
French (fr)
Other versions
EP1506020A2 (en
Inventor
David L Lewis
David B Rozema
Jon A Wolff
James E Hagstrom
Hans Herweijer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrowhead Madison Inc
Original Assignee
Mirus Bio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirus Bio Corp filed Critical Mirus Bio Corp
Publication of EP1506020A2 publication Critical patent/EP1506020A2/en
Publication of EP1506020A4 publication Critical patent/EP1506020A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP03751760A 2002-05-23 2003-05-19 Processes for inhibiting gene expression using polynucleotides Withdrawn EP1506020A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38284202P 2002-05-23 2002-05-23
US382842P 2002-05-23
PCT/US2003/015643 WO2004020577A2 (en) 2002-05-23 2003-05-19 Processes for inhibiting gene expression using polynucleotides

Publications (2)

Publication Number Publication Date
EP1506020A2 EP1506020A2 (en) 2005-02-16
EP1506020A4 true EP1506020A4 (en) 2007-08-29

Family

ID=31978209

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03751760A Withdrawn EP1506020A4 (en) 2002-05-23 2003-05-19 Processes for inhibiting gene expression using polynucleotides

Country Status (2)

Country Link
EP (1) EP1506020A4 (en)
WO (1) WO2004020577A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEWIS D L ET AL: "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 32, September 2002 (2002-09-01), pages 107 - 108, XP002978928, ISSN: 1061-4036 *

Also Published As

Publication number Publication date
WO2004020577A3 (en) 2004-09-23
WO2004020577A2 (en) 2004-03-11
EP1506020A2 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
GB0405884D0 (en) Modified nucleotides
GB0227086D0 (en) Hydrogenation processes
EP1497655A4 (en) Enhanced gene expression system
AU2003218132A8 (en) Microcapillary hybridization chamber
GB2391085B (en) Multi-variable processes
EP1507874A4 (en) Compositions and processes for inhibiting gene expression using polynucleotides
AU2003259185A8 (en) Process for regulating gene expression
AU2003245407A8 (en) Improvements for combinatorial oligonucleotide pcr
EP1506020A4 (en) Processes for inhibiting gene expression using polynucleotides
EP1706490A4 (en) Systems for tightly regulated gene expression
AU2003294705A8 (en) Ntsm gene
GB0223424D0 (en) Disease-associated gene
AU2003238501A8 (en) Hybridization chamber
GB0229139D0 (en) Gene polymorphisms
EP1613722A4 (en) Rna-based inhibitory oligonucleotides
EP1484393A4 (en) Polynucleotide for target gene
HK1253509A1 (en) Modified nucleotides for polynucleotide sequencing
PL374000A1 (en) Improved process for hydroxyazapirones
GB0218089D0 (en) Target DNA
EP1630245A4 (en) Coating method for inhibiting reaction
GB0228086D0 (en) Arrayed polynucleotides
GB0209640D0 (en) Height-related gene
GB0215188D0 (en) Height-related gene
GB0203039D0 (en) Gene
GB0230039D0 (en) Gene

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040715

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MIRUS BIO CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20070731

17Q First examination report despatched

Effective date: 20080201

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100422